TIDMVLG

RNS Number : 6611D

Venture Life Group PLC

21 February 2020

21 February 2020

Venture Life Group plc

("Venture Life" the "Company" or the "Group")

Director/PDMR Shareholding

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that, following his son's eighteenth birthday, Group CEO, Jerry Randall's beneficial interest in ordinary shares of 0.3 pence each of the capital of the Company ("Ordinary Shares") has reduced by 141,000 Ordinary Shares. Accordingly, Jerry Randall now has a beneficial interest in 3,769,729 Ordinary Shares, representing approximately 4.5 per cent. of the Group's issued share capital.

For further information, please contact:

 
 Venture Life Group PLC                               +44(0) 1344 578004 
 Jerry Randall, Chief Executive Officer 
 
 Cenkos Securities plc (Nomad and Broker)             +44(0)20 7397 8900 
 Mark Connelly / Stephen Keys / Cameron MacRitchie 
  (Corporate Finance) 
 Russell Kerr / Michael Johnson (Sales) 
 
 
  Alma PR                                              +44(0)20 3405 0208 
 Rebecca Sanders-Hewett / Hilary Buchanan / 
  Helena Bogle / Jessica Joynson

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHFLFIRFTIIFII

(END) Dow Jones Newswires

February 21, 2020 02:00 ET (07:00 GMT)

Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Venture Life
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Venture Life